Article Information
History
- September 27, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Florian Zeevat, PhD1,2,*,
- Simon van der Pol, PharmD, PhD1,2,
- Tjalke Westra, PhD4,
- Ekkehard Beck, PhD5,
- Maarten J. Postma, PhD1,2,3 and
- Cornelis Boersma, PhD1,2,6
- 1Health-Ecore, Zeist, the Netherlands
- 2University of Groningen, University Medical Center Groningen, Department of Health Sciences, Groningen, the Netherlands
- 3University of Groningen, Department of Economics, Econometrics & Finance, Groningen, the Netherlands
- 4Moderna Netherlands, Amsterdam, the Netherlands
- 5Moderna Inc, Cambridge, MA, USA
- 6Open University, Department of Management Sciences, Heerlen, the Netherlands
- ↵*Corresponding author
Florian Zeevat, Health-Ecore, Utrechtseweg 60, 3704 HE Zeist, the Netherlands, Email: florianzeevat{at}health-ecore.com
Posted September 27, 2024.
Cost-effectiveness analysis of COVID-19 mRNA XBB.1.5 Fall 2023 vaccination in the Netherlands
